Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 37 | 2023 | 2229 | 3.540 |
Why?
|
Cystectomy | 22 | 2023 | 682 | 3.010 |
Why?
|
Prostatic Neoplasms | 35 | 2024 | 11039 | 2.020 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2458 | 1.340 |
Why?
|
Prostatectomy | 12 | 2023 | 1871 | 1.030 |
Why?
|
BCG Vaccine | 3 | 2023 | 367 | 0.980 |
Why?
|
Testicular Neoplasms | 7 | 2023 | 761 | 0.910 |
Why?
|
Carcinoma, Transitional Cell | 6 | 2022 | 798 | 0.810 |
Why?
|
Kallikreins | 2 | 2018 | 258 | 0.720 |
Why?
|
Muscle Neoplasms | 2 | 2019 | 139 | 0.700 |
Why?
|
Carcinoma, Renal Cell | 8 | 2023 | 3123 | 0.690 |
Why?
|
Metformin | 3 | 2017 | 829 | 0.680 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2022 | 106 | 0.640 |
Why?
|
Kidney Neoplasms | 8 | 2023 | 4229 | 0.620 |
Why?
|
Neoplasm Invasiveness | 14 | 2023 | 3612 | 0.620 |
Why?
|
Watchful Waiting | 4 | 2019 | 491 | 0.560 |
Why?
|
Urinary Diversion | 1 | 2016 | 137 | 0.540 |
Why?
|
Laparoscopy | 6 | 2023 | 2121 | 0.480 |
Why?
|
Postoperative Complications | 15 | 2023 | 15244 | 0.470 |
Why?
|
Bacterial Toxins | 2 | 2019 | 933 | 0.460 |
Why?
|
Prostatic Hyperplasia | 2 | 2015 | 522 | 0.460 |
Why?
|
Aftercare | 2 | 2018 | 860 | 0.450 |
Why?
|
Neoadjuvant Therapy | 7 | 2021 | 2721 | 0.420 |
Why?
|
Hypoglycemic Agents | 2 | 2014 | 2866 | 0.410 |
Why?
|
Urologic Neoplasms | 3 | 2019 | 316 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9185 | 0.360 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 484 | 0.360 |
Why?
|
Male | 87 | 2024 | 349538 | 0.360 |
Why?
|
Prostate | 8 | 2023 | 1764 | 0.360 |
Why?
|
Neoplasm Staging | 18 | 2022 | 11001 | 0.350 |
Why?
|
Genetic Engineering | 1 | 2015 | 952 | 0.340 |
Why?
|
Aged | 54 | 2023 | 162944 | 0.320 |
Why?
|
Disease Management | 2 | 2017 | 2450 | 0.310 |
Why?
|
Varicocele | 1 | 2008 | 78 | 0.310 |
Why?
|
Humans | 107 | 2024 | 742088 | 0.300 |
Why?
|
Venous Thromboembolism | 2 | 2018 | 1668 | 0.290 |
Why?
|
Bacterial Proteins | 2 | 2019 | 3843 | 0.270 |
Why?
|
Urothelium | 2 | 2018 | 277 | 0.270 |
Why?
|
Middle Aged | 50 | 2023 | 213127 | 0.260 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2018 | 3471 | 0.250 |
Why?
|
Antibiotic Prophylaxis | 2 | 2023 | 638 | 0.250 |
Why?
|
Incidence | 11 | 2023 | 20928 | 0.250 |
Why?
|
Diagnostic Imaging | 3 | 2015 | 3507 | 0.250 |
Why?
|
Prospective Studies | 18 | 2023 | 53187 | 0.240 |
Why?
|
Androgen Antagonists | 3 | 2017 | 1350 | 0.240 |
Why?
|
Diabetes Mellitus | 3 | 2020 | 5724 | 0.240 |
Why?
|
Evidence-Based Medicine | 2 | 2013 | 3611 | 0.240 |
Why?
|
Orchiectomy | 2 | 2016 | 466 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2011 | 0.220 |
Why?
|
Urinary Retention | 1 | 2023 | 110 | 0.220 |
Why?
|
Lymph Node Excision | 3 | 2023 | 1248 | 0.210 |
Why?
|
Retrospective Studies | 27 | 2023 | 77098 | 0.200 |
Why?
|
Thiohydantoins | 1 | 2021 | 20 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11472 | 0.200 |
Why?
|
Follow-Up Studies | 13 | 2023 | 39004 | 0.190 |
Why?
|
Lower Gastrointestinal Tract | 1 | 2020 | 14 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 7 | 2017 | 6534 | 0.180 |
Why?
|
Length of Stay | 9 | 2020 | 6294 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1509 | 0.180 |
Why?
|
Ileus | 1 | 2020 | 58 | 0.180 |
Why?
|
Urology | 2 | 2017 | 397 | 0.180 |
Why?
|
Blood Transfusion | 4 | 2020 | 1296 | 0.180 |
Why?
|
Vinblastine | 1 | 2021 | 490 | 0.180 |
Why?
|
Leiomyosarcoma | 2 | 2014 | 477 | 0.180 |
Why?
|
Vasectomy | 1 | 2020 | 52 | 0.170 |
Why?
|
Leuprolide | 1 | 2021 | 303 | 0.170 |
Why?
|
Proportional Hazards Models | 10 | 2023 | 12344 | 0.170 |
Why?
|
Southeastern United States | 1 | 2018 | 95 | 0.160 |
Why?
|
Urea | 1 | 2021 | 449 | 0.160 |
Why?
|
Lymphatic Metastasis | 5 | 2018 | 2906 | 0.160 |
Why?
|
Urinary Tract Infections | 2 | 2023 | 786 | 0.160 |
Why?
|
Acrylamide | 1 | 2018 | 60 | 0.160 |
Why?
|
Databases, Factual | 9 | 2019 | 7716 | 0.160 |
Why?
|
Hormone Replacement Therapy | 1 | 2023 | 744 | 0.160 |
Why?
|
Risk Factors | 15 | 2023 | 72145 | 0.160 |
Why?
|
Aged, 80 and over | 20 | 2021 | 57683 | 0.150 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 3070 | 0.150 |
Why?
|
Medical Oncology | 2 | 2020 | 2235 | 0.150 |
Why?
|
Hypogonadism | 1 | 2023 | 798 | 0.150 |
Why?
|
Disease Progression | 8 | 2018 | 13256 | 0.150 |
Why?
|
Muscles | 2 | 2021 | 1617 | 0.150 |
Why?
|
Deoxycytidine | 1 | 2021 | 824 | 0.150 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 546 | 0.150 |
Why?
|
Disease-Free Survival | 4 | 2018 | 6891 | 0.140 |
Why?
|
Treatment Outcome | 19 | 2023 | 62966 | 0.140 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1786 | 0.140 |
Why?
|
Risk Assessment | 11 | 2021 | 23320 | 0.140 |
Why?
|
Poultry | 1 | 2016 | 82 | 0.140 |
Why?
|
Patient Readmission | 4 | 2018 | 3111 | 0.140 |
Why?
|
Odds Ratio | 4 | 2019 | 9846 | 0.140 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8621 | 0.140 |
Why?
|
Conjunctivitis, Inclusion | 1 | 2015 | 5 | 0.140 |
Why?
|
Lysine | 1 | 2021 | 1008 | 0.140 |
Why?
|
Prednisone | 1 | 2021 | 1567 | 0.140 |
Why?
|
Adult | 26 | 2023 | 213712 | 0.140 |
Why?
|
Health Care Costs | 3 | 2018 | 3203 | 0.140 |
Why?
|
Female | 43 | 2023 | 379592 | 0.140 |
Why?
|
Muscle, Smooth | 2 | 2017 | 933 | 0.130 |
Why?
|
Robotics | 1 | 2023 | 892 | 0.130 |
Why?
|
Spheniscidae | 1 | 2015 | 8 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2018 | 21719 | 0.130 |
Why?
|
Aspirin | 2 | 2018 | 3278 | 0.130 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2019 | 365 | 0.130 |
Why?
|
Genome-Wide Association Study | 4 | 2019 | 12220 | 0.130 |
Why?
|
Polyubiquitin | 1 | 2015 | 67 | 0.130 |
Why?
|
Radio Frequency Identification Device | 1 | 2015 | 21 | 0.130 |
Why?
|
Eggs | 1 | 2016 | 184 | 0.130 |
Why?
|
Antitoxins | 1 | 2015 | 82 | 0.130 |
Why?
|
Anticarcinogenic Agents | 1 | 2017 | 253 | 0.130 |
Why?
|
Yersinia enterocolitica | 1 | 1994 | 13 | 0.130 |
Why?
|
Cisplatin | 1 | 2021 | 1637 | 0.130 |
Why?
|
SEER Program | 5 | 2023 | 1507 | 0.130 |
Why?
|
Nephrectomy | 2 | 2018 | 1049 | 0.130 |
Why?
|
Acetaminophen | 1 | 2019 | 544 | 0.120 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 1073 | 0.120 |
Why?
|
Cohort Studies | 9 | 2020 | 40450 | 0.120 |
Why?
|
Doxorubicin | 1 | 2021 | 2215 | 0.120 |
Why?
|
Accidents | 1 | 2015 | 164 | 0.120 |
Why?
|
Methotrexate | 1 | 2021 | 1720 | 0.120 |
Why?
|
Urogenital Neoplasms | 1 | 2015 | 135 | 0.120 |
Why?
|
Hospitals | 2 | 2018 | 3937 | 0.120 |
Why?
|
R Factors | 1 | 2014 | 44 | 0.120 |
Why?
|
Histiocytoma | 1 | 2013 | 5 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1144 | 0.120 |
Why?
|
Rhabdomyolysis | 1 | 2015 | 150 | 0.120 |
Why?
|
Spermatic Cord | 1 | 2013 | 25 | 0.120 |
Why?
|
Chlamydia trachomatis | 1 | 2015 | 245 | 0.120 |
Why?
|
Diet Surveys | 1 | 2018 | 1172 | 0.120 |
Why?
|
Oncogene Proteins, Viral | 1 | 2015 | 362 | 0.120 |
Why?
|
Fishes | 1 | 2016 | 569 | 0.110 |
Why?
|
Carcinoma, Papillary | 1 | 2018 | 781 | 0.110 |
Why?
|
Patient-Centered Care | 1 | 2023 | 1436 | 0.110 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6347 | 0.110 |
Why?
|
Testosterone | 1 | 2023 | 2401 | 0.110 |
Why?
|
Healthcare Disparities | 2 | 2019 | 3151 | 0.110 |
Why?
|
Anemia | 1 | 2022 | 1499 | 0.110 |
Why?
|
Urologic Surgical Procedures | 1 | 2015 | 301 | 0.110 |
Why?
|
Escherichia coli | 2 | 2015 | 4214 | 0.110 |
Why?
|
Hospital Costs | 4 | 2022 | 980 | 0.100 |
Why?
|
Area Under Curve | 1 | 2016 | 1653 | 0.100 |
Why?
|
Denmark | 1 | 2014 | 736 | 0.100 |
Why?
|
Piperidines | 1 | 2020 | 1602 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 4 | 2018 | 35342 | 0.100 |
Why?
|
Body Mass Index | 2 | 2022 | 12695 | 0.100 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15056 | 0.100 |
Why?
|
Telomere | 1 | 2017 | 909 | 0.100 |
Why?
|
Nomograms | 1 | 2013 | 224 | 0.100 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2013 | 256 | 0.100 |
Why?
|
Perioperative Care | 1 | 2018 | 997 | 0.100 |
Why?
|
Mass Screening | 2 | 2024 | 5238 | 0.090 |
Why?
|
Administration, Intravesical | 2 | 2022 | 91 | 0.090 |
Why?
|
United States | 14 | 2024 | 69693 | 0.090 |
Why?
|
MicroRNAs | 2 | 2019 | 3731 | 0.090 |
Why?
|
Rhabdomyosarcoma | 1 | 2013 | 382 | 0.090 |
Why?
|
Liposarcoma | 1 | 2013 | 333 | 0.090 |
Why?
|
Biofeedback, Psychology | 1 | 2011 | 115 | 0.090 |
Why?
|
Registries | 2 | 2018 | 8077 | 0.090 |
Why?
|
Minority Groups | 1 | 2018 | 1215 | 0.090 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7153 | 0.090 |
Why?
|
HEK293 Cells | 2 | 2019 | 4200 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 17400 | 0.090 |
Why?
|
Urination Disorders | 1 | 2011 | 241 | 0.090 |
Why?
|
Survival Rate | 6 | 2020 | 12773 | 0.090 |
Why?
|
Diet | 2 | 2018 | 7923 | 0.080 |
Why?
|
Prognosis | 8 | 2018 | 29010 | 0.080 |
Why?
|
Genome, Bacterial | 1 | 2013 | 754 | 0.080 |
Why?
|
Pain, Postoperative | 1 | 2019 | 1638 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1967 | 0.080 |
Why?
|
ROC Curve | 1 | 2016 | 3528 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3239 | 0.080 |
Why?
|
Time Factors | 6 | 2020 | 40054 | 0.080 |
Why?
|
Immunotherapy | 1 | 2023 | 4414 | 0.080 |
Why?
|
Movement | 1 | 2015 | 1470 | 0.080 |
Why?
|
Guideline Adherence | 2 | 2017 | 2266 | 0.080 |
Why?
|
DNA Replication | 1 | 2014 | 1397 | 0.070 |
Why?
|
Escherichia coli Proteins | 1 | 2014 | 1052 | 0.070 |
Why?
|
Propensity Score | 3 | 2019 | 1771 | 0.070 |
Why?
|
Survival Analysis | 5 | 2019 | 10248 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5304 | 0.070 |
Why?
|
Drug Resistance, Bacterial | 1 | 2014 | 1032 | 0.070 |
Why?
|
Cell Division | 1 | 2014 | 4564 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2019 | 15494 | 0.070 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13655 | 0.070 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 4801 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2015 | 6608 | 0.070 |
Why?
|
Internship and Residency | 2 | 2016 | 5774 | 0.070 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2013 | 910 | 0.070 |
Why?
|
Urinary Bladder | 2 | 2022 | 1171 | 0.060 |
Why?
|
Suicide | 1 | 2015 | 1475 | 0.060 |
Why?
|
Age Factors | 2 | 2019 | 18355 | 0.060 |
Why?
|
Drug Prescriptions | 1 | 2014 | 1636 | 0.060 |
Why?
|
Testis | 1 | 2008 | 800 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 14720 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2366 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4839 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4664 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2015 | 3020 | 0.060 |
Why?
|
Immunity, Innate | 1 | 2015 | 2956 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2015 | 1873 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2016 | 3527 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2019 | 10472 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2016 | 3679 | 0.060 |
Why?
|
Retroperitoneal Space | 1 | 2023 | 172 | 0.060 |
Why?
|
Apoptosis | 2 | 2019 | 9715 | 0.060 |
Why?
|
Logistic Models | 4 | 2020 | 13403 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 4328 | 0.060 |
Why?
|
Contrast Media | 2 | 2013 | 5295 | 0.050 |
Why?
|
Organ Size | 1 | 2008 | 2253 | 0.050 |
Why?
|
Mycobacterium tuberculosis | 1 | 2013 | 1825 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2283 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2023 | 178 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 1769 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2017 | 12242 | 0.050 |
Why?
|
Mutation | 2 | 2018 | 29717 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2015 | 13921 | 0.050 |
Why?
|
Drug Utilization Review | 1 | 2003 | 245 | 0.050 |
Why?
|
Uganda | 2 | 2016 | 1239 | 0.050 |
Why?
|
Obesity | 1 | 2022 | 12705 | 0.040 |
Why?
|
Insulin | 1 | 2014 | 6575 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2003 | 880 | 0.040 |
Why?
|
Blotting, Western | 2 | 2019 | 5180 | 0.040 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2023 | 454 | 0.040 |
Why?
|
Genomics | 3 | 2021 | 5692 | 0.040 |
Why?
|
Decision Making | 1 | 2013 | 3869 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 546 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4554 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13019 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 628 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 3915 | 0.040 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2004 | 685 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9639 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12958 | 0.040 |
Why?
|
Doxycycline | 1 | 2019 | 326 | 0.040 |
Why?
|
Positron-Emission Tomography | 3 | 2023 | 6259 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 792 | 0.040 |
Why?
|
Melanoma | 1 | 2015 | 5462 | 0.040 |
Why?
|
Heart Valve Diseases | 1 | 2004 | 1067 | 0.040 |
Why?
|
Aorta | 1 | 2004 | 2057 | 0.040 |
Why?
|
Surgical Wound Dehiscence | 1 | 2017 | 215 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5662 | 0.030 |
Why?
|
Breeding | 1 | 2015 | 51 | 0.030 |
Why?
|
Computational Biology | 2 | 2019 | 3518 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2020 | 494 | 0.030 |
Why?
|
Yersinia Infections | 1 | 1994 | 9 | 0.030 |
Why?
|
Adolescent | 6 | 2017 | 85649 | 0.030 |
Why?
|
Perioperative Period | 1 | 2016 | 256 | 0.030 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2004 | 1384 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13853 | 0.030 |
Why?
|
Canada | 2 | 2003 | 2061 | 0.030 |
Why?
|
Child | 6 | 2016 | 77478 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2018 | 11695 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2019 | 5310 | 0.030 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2004 | 1527 | 0.030 |
Why?
|
Cell Death | 1 | 2019 | 1695 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2023 | 1538 | 0.030 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2019 | 1119 | 0.030 |
Why?
|
Cats | 1 | 1994 | 998 | 0.030 |
Why?
|
Urethra | 1 | 2015 | 408 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2017 | 1179 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1661 | 0.030 |
Why?
|
Automation | 1 | 2015 | 584 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2017 | 963 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 681 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3510 | 0.030 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2012 | 233 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 9941 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2015 | 0.020 |
Why?
|
Stents | 1 | 2023 | 3276 | 0.020 |
Why?
|
Quality Improvement | 2 | 2016 | 3738 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2014 | 572 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2013 | 414 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6483 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3300 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2014 | 2645 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10372 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 1940 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4187 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2016 | 2876 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1185 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2924 | 0.020 |
Why?
|
Phenotype | 2 | 2017 | 16331 | 0.020 |
Why?
|
Eating | 1 | 2016 | 1535 | 0.020 |
Why?
|
Dogs | 1 | 1994 | 3910 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1533 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1167 | 0.020 |
Why?
|
Young Adult | 4 | 2017 | 56350 | 0.020 |
Why?
|
Leukocytes | 1 | 2017 | 2039 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3418 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2018 | 1575 | 0.020 |
Why?
|
Fibrosis | 1 | 2015 | 2026 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2015 | 1780 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 1994 | 1871 | 0.020 |
Why?
|
Cattle | 1 | 1994 | 3923 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2372 | 0.020 |
Why?
|
Anticoagulants | 1 | 2023 | 4595 | 0.020 |
Why?
|
Child, Preschool | 3 | 2016 | 40955 | 0.020 |
Why?
|
Heart Defects, Congenital | 1 | 2004 | 4566 | 0.020 |
Why?
|
Elasticity Imaging Techniques | 1 | 2012 | 388 | 0.020 |
Why?
|
Genetic Loci | 1 | 2017 | 2572 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1052 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2739 | 0.020 |
Why?
|
Lung Diseases | 1 | 2017 | 1884 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5385 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3711 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2015 | 1707 | 0.020 |
Why?
|
Urinary Incontinence | 1 | 2011 | 494 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3740 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4214 | 0.020 |
Why?
|
Smoking | 1 | 2023 | 8969 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2016 | 2566 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10392 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2016 | 25575 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15994 | 0.020 |
Why?
|
Health Personnel | 1 | 2018 | 3210 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12017 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2015 | 1204 | 0.020 |
Why?
|
Hemorrhage | 1 | 2016 | 3461 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4211 | 0.020 |
Why?
|
Risk | 1 | 2016 | 9679 | 0.010 |
Why?
|
Critical Care | 1 | 2016 | 2640 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9305 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
Infant | 2 | 2016 | 35070 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19862 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3667 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9410 | 0.010 |
Why?
|
Base Sequence | 1 | 2014 | 12797 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 3760 | 0.010 |
Why?
|
Ultrasonography | 1 | 2015 | 5978 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 7901 | 0.010 |
Why?
|
Image Enhancement | 1 | 2012 | 2921 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20086 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 18112 | 0.010 |
Why?
|
Drug Labeling | 1 | 2003 | 231 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1420 | 0.010 |
Why?
|
Hospital Information Systems | 1 | 2003 | 395 | 0.010 |
Why?
|
Hospitalization | 1 | 2019 | 10232 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9581 | 0.010 |
Why?
|
Animals | 3 | 2016 | 168561 | 0.010 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2003 | 430 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15108 | 0.010 |
Why?
|
Quality of Life | 1 | 2018 | 12730 | 0.010 |
Why?
|
Aortic Valve | 1 | 2004 | 1911 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 23387 | 0.010 |
Why?
|